Reply to: “Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study” and “Methodologic and Reporting Gaps in the SURF Trial”

Yoshikuni Kawaguchi

Yoshikuni Kawaguchi, MD, PhD, MPH, MMA, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Kosuke Kashiwabara, PhD, Biostatistics Division, Central Coordinating Unit, Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; Yutaka Matsuyama, PhD, Department of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan; Norihiro Kokudo, MD, PhD, National Center for Global Health and Medicine, Tokyo, Japan; and Kiyoshi Hasegawa, MD, PhD, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Kosuke Kashiwabara

Yutaka Matsuyama

Yoshikuni Kawaguchi, MD, PhD, MPH, MMA, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Kosuke Kashiwabara, PhD, Biostatistics Division, Central Coordinating Unit, Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; Yutaka Matsuyama, PhD, Department of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan; Norihiro Kokudo, MD, PhD, National Center for Global Health and Medicine, Tokyo, Japan; and Kiyoshi Hasegawa, MD, PhD, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Norihiro Kokudo

National Center for Global Health and Medicine, Tokyo, Japan

Kiyoshi Hasegawa

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Tokyo University, Tokyo, Japan